Truist initiated coverage of Ascentage Pharma with a rating of Buy

BTIG Research initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $50.00

Piper Sandler initiated coverage of Ascentage Pharma with a rating of Overweight and set a new price target of $48.00

Analyst initiated coverage of Ascentage Pharma with a rating of Overweight

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

S-8 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

S-8 POS - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company's novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), by the renowned scientific journal Signal Transduction and Targeted Therapy (Im

ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences in December 2025. Piper Sandler 37th Annual Healthcare Conference: Fireside chat at 9:00 am EST on December 2ndEvercore ISI HealthCONx Conference: Fireside chat at 3:50 pm EST on December 3rdCiti 2025 Global Hea

ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that the latest results from multiple clinical studies of its novel drug, olverembatinib (HQP1351), have been selected for presentations at the 67th American Society of Hematology (ASH) Annual Meeting, marking the eighth consecutive year in which clinical data on olverembatinib have been selected by ASH for the Annual Meeting. This year, multiple

ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that the latest results from two clinical studies of its novel drug, lisaftoclax (APG-2575), have been selected for presentations, including an oral report, at the 67th American Society of Hematology (ASH) Annual Meeting. This is the fourth consecutive year in which clinical results on lisaftoclax have been selected by the ASH Annual Meeting. Thi

ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST About Ascenta

ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in October 2025. Piper Sandler Virtual Oncology Symposium: Fireside chat at 10:30 am EDT on October 10J.P. Morgan Global Healthcare Shanghai Conference: One-on-one and group investor meetings on October 16-172025 BofA China

ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in September 2025. Citi's 2025 Biopharma Back to School: Fireside chat at 4:00 pm EDT on September 3Cantor Global Healthcare Conference 2025: Fireside chat at 2:45 pm EDT on September 4H.C. Wainwright 27th Annual Global Inv

Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China's NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitorsRegistrational Phase III trial for 1L HR MDS (GLORA-4) cleared by FDA and EMA, and first patients enrolled in Europe and ChinaCompleted a top-up placement in July 2025, resulting in US$190.1 million in net proceedsNine registrational clinical trials are in progress, including thr

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic

ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug

ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he